Sugi Predict

Sugi Predict / Compounds / SCHEMBL1441024

SCHEMBL1441024

SCHEMBL1441024

CCCc1ccc(C[O])cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 1/20 0.52
▸ LPL P06858 2/20 0.50
▸ LIPG Q9Y5X9 2/20 0.50
▸ MGLL Q99685 1/20 0.48
▸ PLK1 P53350 1/20 0.48
▸ THRB P10828 2/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ CNR1 P21554 1/20 0.43
▸ CNR2 P34972 1/20 0.43
▸ ALDH1A1 P00352 3/20 0.42
▸ POLB P06746 2/20 0.42
▸ CTDSP1 Q9GZU7 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ NPC1 O15118 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ GPR84 Q9NQS5 1/20 0.40
▸ MCL1 Q07820 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9486125 0.86 ALDH1A1 (0.52) CA2LPLLIPGMGLLPLK1
SCHEMBL142480 0.85 LPL (0.62) CA2LPLLIPGMGLLPLK1
SCHEMBL2092858 0.84 ALDH1A1 (0.57) CA2PLK1THRBALDH1A1KDM4E
SCHEMBL10344423 0.83 CA2 (0.52) CA2LPLLIPGMGLLPLK1
Water SCHEMBL28941509 0.82 LPL (0.59) CA2LPLLIPGMGLLPLK1
SCHEMBL9839848 0.82 LPL (0.59) CA2LPLLIPGMGLLPLK1
SCHEMBL9219490 0.80 ALDH1A1 (0.63) CA2LPLLIPGMGLLTHRB
SCHEMBL6670812 0.80 ALDH1A1 (0.63) CA2LPLLIPGMGLLTHRB
SCHEMBL27686987 0.80 ALDH1A1 (0.63) CA2LPLLIPGMGLLTHRB
SCHEMBL9633161 0.79 LPL (0.46) CA2LPLLIPGMGLLPLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12024536-B2 C-terminal HSP90 inhibitors UNIVERSITY OF KANSAS (US) 2024-07-02 — — US disclosed
US-20230102047-A1 C-TERMINAL HSP90 INHIBITORS REATA PHARMACEUTICALS, INC. 2023-03-30 — — US disclosed
US-11390640-B2 C-terminal Hsp90 inhibitors UNIVERSITY OF KANSAS (US) 2022-07-19 — — US disclosed
CN-113694074-A Compositions of selenium organic compounds and methods of use thereof 全技术公司 2021-11-26 — — CN disclosed
EP-3144001-B1 COMPOSITIONS OF SELENOORGANIC COMPOUNDS AND METHODS OF USE THEREOF ALLTECH INC (US) 2021-08-11 — — EP disclosed
US-20210188891-A1 C-TERMINAL HSP90 INHIBITORS REATA PHARMACEUTICALS, INC. 2021-06-24 — — US disclosed
CN-107474085-B Hsp 90C-terminal inhibitor and pharmaceutical composition and application thereof 堪萨斯大学 2021-05-11 — — CN disclosed
US-10882881-B2 C-terminal Hsp90 inhibitors UNIVERSITY OF KANSAS (US) 2021-01-05 — — US disclosed
CN-106822168-B Compositions of selenium-containing organic compounds and methods of use thereof 全技术公司 2020-11-27 — — CN disclosed
US-20200283465-A1 C-TERMINAL HSP90 INHIBITORS REATA PHARMACEUTICALS, INC. 2020-09-10 — — US disclosed
WO-2000018724-A1 (R)-CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO-(n+1)-ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY MONSANTO COMPANY (US) 2000-04-06 — — WO disclosed
WO-2000018723-A1 SUBSTITUTED N-ALIPHATIC-N-AROMATIC TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY MONSANTO COMPANY (US) 2000-04-06 — — WO disclosed
US-4537720-A N-substituted-2-(R)-(sulfinic acid)-3-(S)-(acylamino)-4-oxo-azetidines and process ELI LILLY AND COMPANY (US) 1985-08-27 — — US disclosed
US-4477660-A 7-(S)-Acylaminocephalosporin sulfones and process ELI LILLY AND COMPANY (US) 1984-10-16 — — US disclosed
US-4474879-A Process for 3-hydroxymethyl cephalosporin sulfones ELI LILLY AND COMPANY (US) 1984-10-02 — — US disclosed
US-4459405-A Desacetylcephalosporin sulfones ELI LILLY AND COMPANY (US) 1984-07-10 — — US disclosed
EP-0109816-A1 N-substituted-2-(R)-(sulfinic acid)-3-(S)-(acylamido)-4-oxo-azetidines and process ELI LILLY AND COMPANY (US) 1984-05-30 — — EP disclosed
EP-0109301-A2 7-(S)-acylaminocephalosporin sulfones and process ELI LILLY AND COMPANY (US) 1984-05-23 — — EP disclosed
EP-0109300-A2 Desacetylcephalosporin sulfones ELI LILLY AND COMPANY (US) 1984-05-23 — — EP disclosed
US-4436596-A N-Substituted-2-(R)-(sulfinic acid)-3-(S)-(acylamido)-4-oxo-azetidines and process ELI LILLY AND COMPANY (US) 1984-03-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10882881-B2 C-terminal Hsp90 inhibitors HSP90AB2P, HSP90AB1, HSP90B1 CA2 4338/4885LPL 1939/4885LIPG 1183/4885
US-11390640-B2 C-terminal Hsp90 inhibitors HSP90AB2P, HSP90AB1, HSP90B1 CA2 4338/4885LPL 1939/4885LIPG 1183/4885
US-20230102047-A1 C-TERMINAL HSP90 INHIBITORS HSP90AB2P, HSP90AB1, HSP90B1 CA2 4338/4885LPL 1939/4885LIPG 1183/4885
US-12024536-B2 C-terminal HSP90 inhibitors HSP90AB2P, HSP90AB1, HSP90B1 CA2 4338/4885LPL 1939/4885LIPG 1183/4885
US-20210188891-A1 C-TERMINAL HSP90 INHIBITORS HSP90AB2P, HSP90AB1, HSP90B1 CA2 4338/4885LPL 1939/4885LIPG 1183/4885
US-20200283465-A1 C-TERMINAL HSP90 INHIBITORS HSP90AB2P, HSP90AB1, HSP90B1 CA2 4338/4885LPL 1939/4885LIPG 1183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.